Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Neoplasms 51%
3. Transforming Growth Factors 35%
4. ErbB Receptors 32%
5. Trastuzumab 26%
6. Phosphatidylinositol 3-Kinase 26%
7. Protein-Tyrosine Kinases 23%
8. Estrogen Receptors 22%
9. Breast 18%
10. Mutation 18%
11. Phosphatidylinositol 3-Kinases 17%
12. Therapeutics 16%
13. human ERBB2 protein 16%
14. Phosphotransferases 15%
15. Growth 15%
16. Estrogen Receptor Modulators 15%
17. Colorectal Neoplasms 15%
18. Lapatinib 14%
19. Letrozole 14%
20. Early Detection of Cancer 14%
21. Estrogens 13%
22. Ligands 13%
23. Triple Negative Breast Neoplasms 12%
24. Disclosure 11%
25. Heterografts 10%
26. Rhabdomyosarcoma 10%
27. Hormones 9%
28. Tamoxifen 9%
29. Epithelial Cells 9%
30. Phosphorylation 9%
31. Fulvestrant 9%
32. Survival 8%
33. Oncogenes 8%
34. N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 8%
35. Hispanic Americans 8%
36. Pharmaceutical Preparations 8%
37. Clinical Trials 8%
38. Growth Factor Receptors 8%
39. Emotions 8%
40. Cell Line 8%
41. Biomarkers 8%
42. ribociclib 7%
43. Alpelisib 7%
44. Cell Movement 7%
45. Gefitinib 7%
46. Mitogen-Activated Protein Kinase Kinases 7%
47. NVP-BKM120 7%
48. Drug Therapy 7%
49. Receptor Protein-Tyrosine Kinases 7%
50. Colonoscopy 7%
51. Antibodies 7%
52. Neoplasm Metastasis 6%
53. MCF-7 Cells 6%
54. Carcinogenesis 6%
55. Herniorrhaphy 6%
56. Cancer Survivors 6%
57. Child 5%
58. Cell Proliferation 5%
59. Down-Regulation 5%
60. Apoptosis 5%
61. Genes 5%
62. Cell Survival 5%
63. Proteins 5%
64. Inguinal Hernia 5%
65. IGF Type 1 Receptor 5%
66. Nude Mice 5%
67. 3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid 5%
68. Intercellular Signaling Peptides and Proteins 5%
69. Local Anesthesia 5%
70. Aromatase Inhibitors 5%
71. Up-Regulation 5%